All In Biotech

Drug Trial Radar · NCT06873945

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 674 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

674

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Mar 19, 2028

Study completion Mar 19, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is seeking participants who: * Are 12 years of age or older (Part 1) * Are 12 to less than 18 years (Part 2) * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata About 550 participants will take part in Part 1 of this study. About 80 participants will take part in Part 2 of this study. In Part 1, participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily. The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective. In Part 2, all eligible participants will receive ritlecitinib 100 mg taken by mouth once daily. The data from this part of the study will be combined with the data from Part 1 of the study to help to see if the 100 mg dose of ritlecitinib is safe and effective in adolescent patients with alopecia areata. People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes (Part 1 only). Participants will also be asked to complete questionnaires about their alopecia areata.

Conditions

  • Alopecia Areata

Interventions

  • Ritlecitinib 100 mgDrug

    100 mg Capsule

  • Ritlecitinib 50 mgDrug

    50 mg Capsule

  • Placebo - 100 mgDrug

    Capsule (to match Ritlecitinib 100 mg)

  • Placebo - 50 mgDrug

    Capsule (to match Ritlecitinib 50 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20Time frame: Week 24
  2. Part 2: Percentage of participants with TEAEs, SAEs, and AEs leading to discontinuationTime frame: Baseline to Follow-up visit (Week 52)
  3. Part 2: Percentage of participants with clinically significant laboratory abnormalitiesTime frame: Baseline to Follow-up visit (Week 52)

Locations

148 sites in 11 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic of UAB Hospital (Radiology)

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham Faculty Office Towers (Regulatory)

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas · Active not recruiting

  • Doc1 Healthcare Systems

    Brea, California · Recruiting

  • California Dermatology & Clinical Research Institute

    Encinitas, California · Active not recruiting

  • Marvel Clinical Research

    Huntington Beach, California · Active not recruiting

  • University of California - Irvine

    Irvine, California · Recruiting

  • Gavin Herbert Eye Institute

    Irvine, California · Recruiting

  • Southern California Clinical Research

    Santa Ana, California · Active not recruiting

  • Brett King MD, LLC

    Fairfield, Connecticut · Recruiting

  • Alliance for Multispecialty Research, LLC

    Fort Myers, Florida · Active not recruiting

  • Robert B. Pritt, DO, PA

    Fort Myers, Florida · Active not recruiting

  • Pediatric Skin Research

    Miami, Florida · Recruiting

  • Skin Research of South Florida

    Miami, Florida · Recruiting

  • ForCare Clinical Research

    Tampa, Florida · Active not recruiting

  • Olympian Clinical Research - Tampa - Memorial Highway

    Tampa, Florida · Active not recruiting

  • Endeavor Health Audiology -CHICAGO

    Chicago, Illinois · Recruiting

  • Endeavor Health Audiology -LAKE BLUFF

    Lake Bluff, Illinois · Recruiting

  • Endeavor Health Audiology-NORTHBROOK

    Northbrook, Illinois · Recruiting

  • Endeavor Health Audiology-SKOKIE

    Skokie, Illinois · Recruiting

  • Endeavor Health Imaging & Radiology Serviccs - Old Orchard

    Skokie, Illinois · Recruiting

  • Endeavor Health Lab Services - Old Orchard

    Skokie, Illinois · Recruiting

  • Endeavor Health

    Skokie, Illinois · Recruiting

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Callender Center for Clinical Research

    Glenn Dale, Maryland · Active not recruiting

  • Dermatology and Skin Cancer Specialists, LLC

    Rockville, Maryland · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Active not recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Active not recruiting

  • The General Hospital Corporation d/b/a Massachusetts General Hospital

    Boston, Massachusetts · Active not recruiting

  • Revival Research Institute, LLC

    Troy, Michigan · Active not recruiting

  • University of Minnesota Clinics and Surgery Center Department of Radiology

    Minneapolis, Minnesota · Recruiting

  • University of Minnesota Clinics and Surgery Center Department of Audiology

    Minneapolis, Minnesota · Recruiting

  • University of Minnesota Clinics and Surgery Center Department of Radiology

    Minneapolis, Minnesota · Recruiting

  • University of Minnesota Health Clinical Research Unit (M Health CRU)

    Minneapolis, Minnesota · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • UNC Dermatology and Skin Cancer Center

    Chapel Hill, North Carolina · Active not recruiting

  • Clinical & Translational Research Center (CTRC)

    Chapel Hill, North Carolina · Active not recruiting

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.